FIELD: medicine.
SUBSTANCE: invention refers to biotechnology. Method includes cultivation of transplantable cells MDCK in nutrient medium, production of virus-containing substances by cultivation vaccinating influenza virus strains in MDCK cells culture on the same nutrient medium, virus substance purification from ballast impurities, stabilising additives introduction to purified substance and drying of the finished vaccine form. Thus inoculation dose of transplantable cells MDCK is 100-600 thousand cells per 1 ml of environment. Vaccinating cold-adapted reasortants of influenza virus strains are used as virus strains with inoculation dose of infection multiplicity 0.01-0.0001 "ЭИД50/КЛ-". Serum-free nutrient medium added with soya hydrolysate concentrated 0.01-10% and proteolytic enzyme in amount 0.25-50.0 mkg/ml prior to introduction of influenza virus strains inoculation dose is used as nutrient medium for cultivation of MDCK cells and influenza virus strains on specified cells. Cultivation of MDCK cells cultures and cold-adapted influenza virus strains in specified cell culture is performed in suspensions on microcarriers brought in serum-free nutrient medium in concentration 1-6 g/l. Collection of virus-containing liquid is carried out after specific activity of influenza virus is not less than 8.0 lg "ЭИД"50/ml. Saccharose and soya peptone in final concentration (5-10) and (3-8) mass % respectively are used as stabilising additives introduced into purified substance before drying.
EFFECT: method enables to produce vaccine with lower content of foreign animal protein components.
7 cl, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF OBTAINING LIFE CULTURE VACCINE AGAINST INFLUENZA VIRUS | 2009 |
|
RU2420314C1 |
| METHOD OF OBTAINING MICROENCAPSULATED FORMS OF LIVE CULTURE VACCINE AGAINST SEASONAL AND PANDEMIC INFLUENZA FOR INTRANASAL USE | 2016 |
|
RU2617051C1 |
| ATTENUATED COLD-ADAPTED STRAIN OF INFLUENZA VIRUS A/KRASNODAR/101/59/35(H2N2) FOR OBTAINING STRAINS OF LIVE INTRANASAL INFLUENZA VACCINE | 2007 |
|
RU2354695C1 |
| COLD-ADAPTED INFLUENZA VIRUS STRAIN B-B/VICTORIA/2/63/87 INTENDED AS STRAIN-DONOR OF ATTENUATION FOR OBTAINING REASSORTANTS OF COLD-ADAPTED STRAINS FOR LIVE INFLUENZA VACCINE | 2013 |
|
RU2529772C1 |
| INFLUENZA VIRUS STRAIN A/Hongkong/1/68/162/35 (H3N2) - UNIVERSAL DONOR OF INTERNAL GENES FOR REASSORTANTS, AND REASSORTANT STRAINS A/SPB/GK/09 (H1N1) AND A/HK/Astana/6:2/2010 (H5N1) PREPARED THEREOF | 2011 |
|
RU2511431C2 |
| ATTENUATED COLD-ADAPTED INFLUENZA VIRUS STRAIN A/PR/8/59/M2 (H1N1) APPLICABLE FOR VACCINAL INFLUENZA VIRUS STRAINS AS ATTENUATION DONOR, VACCINAL INFLUENZA VIRUS STRAINS A/59/M2/CALIFORNIA/66/2211 (H2N2) AND A/59/M2/TOKYO/67/22111 (H2N2) | 2011 |
|
RU2556833C2 |
| INFLUENZA VIRUS STRAIN A/17/Anui/2013/61 (H7N9) FOR PRODUCTION OF LIVE INTRANASAL INFLUENZA VACCINE | 2013 |
|
RU2563351C2 |
| REASSORTANT INFLUENZA VIRUS STRAIN RN9/13-HUMAN A(H6N9) FOR NEURAMINIDASE ANTIBODY ASSAY IN INFLUENZA INFECTION AND VACCINATION | 2014 |
|
RU2587629C1 |
| VACCINE STRAIN OF INFLUENZA VIRUS A/17/SLOVENIA/2015/1121 (H1N1)PDM09 FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2019 |
|
RU2724706C1 |
| VACCINE INFLUENZA VIRUS A/17/SOUTH AFRICA/2013/01 (H1N1)PDM09 FOR PRODUCTION OF LIVE INTRANASAL INFLUENZA VACCINE FOR ADULTS AND CHILDREN | 2016 |
|
RU2627188C1 |
